Medpace Holdings, Inc. $MEDP Shares Sold by Boston Trust Walden Corp

Medpace logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Boston Trust Walden cut its Medpace stake by 6.9% in the third quarter, selling 10,674 shares and retaining 144,843 shares worth about $90.4 million.
  • Medpace beat quarterly earnings estimates, reporting EPS of $4.84 versus $4.44 expected, while revenue rose 8.5% year over year to $716 million.
  • Analysts’ consensus rating is Hold, with an average price target of $649.27; company insiders sold 342,647 shares worth about $213.6 million over the past 90 days.
  • MarketBeat previews the top five stocks to own by December 1st.

Boston Trust Walden Corp lowered its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 6.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 144,843 shares of the company's stock after selling 10,674 shares during the quarter. Boston Trust Walden Corp owned about 0.52% of Medpace worth $90,408,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Johnson Financial Group Inc. bought a new stake in shares of Medpace during the second quarter worth $27,000. Jones Financial Companies Lllp bought a new stake in Medpace in the 2nd quarter valued at $30,000. Allied Private Wealth LLC bought a new stake in Medpace in the 2nd quarter valued at $31,000. Kilter Group LLC bought a new stake in Medpace in the 2nd quarter valued at $31,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Medpace in the 2nd quarter worth $34,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on MEDP. Barclays increased their target price on Medpace from $625.00 to $675.00 and gave the stock an "equal weight" rating in a report on Friday, October 23rd. UBS Group lifted their price target on Medpace from $673.00 to $700.00 and gave the company a "neutral" rating in a research note on Friday, October 23rd. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Mizuho set a $730.00 price objective on Medpace in a report on Friday, October 23rd. Finally, TD Cowen increased their price objective on Medpace from $492.00 to $673.00 and gave the stock a "hold" rating in a report on Friday, October 23rd. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $649.27.

Get Our Latest Analysis on Medpace

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $656.77 on Thursday. The stock has a 50 day moving average price of $621.39 and a 200 day moving average price of $531.95. The stock has a market capitalization of $18.37 billion, a PE ratio of 36.41, a price-to-earnings-growth ratio of 2.57 and a beta of 1.12. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $693.97.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, topping the consensus estimate of $4.44 by $0.40. Medpace had a return on equity of 99.76% and a net margin of 18.24%. The firm had revenue of $716.00 million for the quarter, compared to analyst estimates of $714.47 million. During the same quarter in the previous year, the firm earned $3.86 EPS. The business's quarterly revenue was up 8.5% on a year-over-year basis. As a group, research analysts forecast that Medpace Holdings, Inc. will post 18.06 EPS for the current year.

Insider Activity

In related news, VP Susan Burwig sold 3,940 shares of the firm's stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $677.00, for a total value of $2,667,380.00. Following the completion of the transaction, the vice president directly owned 54,012 shares of the company's stock, valued at approximately $36,566,124. This trade represents a 6.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Stephen Ewald sold 1,245 shares of the business's stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $690.00, for a total transaction of $859,050.00. Following the transaction, the general counsel owned 19,098 shares in the company, valued at approximately $13,177,620. The trade was a 6.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 342,647 shares of company stock valued at $213,561,374. 20.50% of the stock is owned by insiders.

Medpace Company Profile

(Free Report)

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace's services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

Read More

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Medpace Right Now?

Before you consider Medpace, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.

While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines